• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cytek Biosciences Inc.

    2/28/25 4:45:01 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTKB alert in real time by email
    S-8 1 d918363ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 28, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Cytek Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-2547526

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    47215 Lakeview Boulevard

    Fremont, California 94538

    (Address of Principal Executive Offices) (Zip Code)

    Cytek Biosciences, Inc. 2021 Equity Incentive Plan

    Cytek Biosciences, Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plans)

    Wenbin Jiang, Ph.D.

    President and Chief Executive Officer

    Cytek Biosciences, Inc.

    47215 Lakeview Boulevard

    Fremont, California 94538

    (877) 922-9835

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Please send copies of all communications to:

     

    Gordon K. Ho

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     

    Valerie Barnett

    Chief Legal Officer

    Cytek Biosciences, Inc.

    47215 Lakeview Boulevard

    Fremont, California 94538

    (877) 922-9835

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
    Emerging growth company   ☐     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, Cytek Biosciences, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) to register 5,168,236 additional shares of common stock under the Registrant’s 2021 Equity Incentive Plan and 1,292,059 additional shares of common stock under the Registrant’s 2021 Employee Stock Purchase Plan pursuant to the provisions of those plans providing for an automatic increase in the number of shares reserved for issuance under such plans on January 1 of each year pursuant to a specified formula. This Registration Statement hereby incorporates by reference the contents of the Registrant’s prior registration statements on Form S-8 filed with the Commission on March  14, 2024 (Registration No. 333-277936), March  2, 2023 (Registration No. 333-270200), March  17, 2022 (Registration No. 333-263661) and  July 23, 2021 (Registration No. 333-258153).

    PART II

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

    The following documents filed by Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on  Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025; and

    (b) The description of the Registrant’s Common Stock contained in the registration statement on Form 8-A registering the Registrant’s Common Stock under Section 12 of the Exchange Act filed with the Commission on July 19, 2021, including any amendments or reports filed for purposes of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    II-2


    ITEM 8. EXHIBITS.

    The following exhibits are filed herewith:

     

              Incorporated by Reference  

    Exhibit

    Number

      

    Exhibit Description

       Form      File No.      Exhibit      Filing Date      Filed
    Herewith
     
     4.1    Amended and Restated Certificate of Incorporation of Cytek Biosciences, Inc.      8-K        001-40632        3.1        7/27/2021     
     4.2    Amended and Restated Bylaws of Cytek Biosciences, Inc.      8-K        001-40632        3.2        7/27/2021     
     4.3    Form of common stock certificate of Cytek Biosciences, Inc.      S-1/A        333-257663        4.1        7/19/2021     
     5.1    Opinion of Cooley LLP                  X  
    23.1    Consent of Cooley LLP (included in Exhibit 5.1)                  X  
    23.2    Consent of Independent Registered Public Accounting Firm                  X  
    24.1    Power of Attorney (included on the signature page of this Registration Statement)                  X  
    99.1    Cytek Biosciences, Inc. 2021 Equity Incentive Plan      S-1/A        333-257663        10.4        7/19/2021     
    99.2    Forms of Option Agreement and Notice of Stock Option Grant under 2021 Equity Incentive Plan      S-1/A        333-257663        10.5        7/19/2021     
    99.3    Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan      10-Q        001-40632        10.2        11/12/2021     
    99.4    Forms of Option Agreement and Notice of Stock Option Grant under 2021 Equity Incentive Plan, effective August 23, 2022.      10-Q        001-40632        10.1        11/09/2022     
    99.5    Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan, effective August 23, 2022.      10-Q        001-40632        10.2        11/09/2022     
    99.6    Cytek Biosciences, Inc. 2021 Employee Stock Purchase Plan      S-1/A        333-257663        10.6        7/19/2021     
    107    Filing Fee Table                  X  

     

    II-3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on February 28, 2025.

     

    CYTEK BIOSCIENCES, INC.

    /s/ Wenbin Jiang, Ph.D.

    Wenbin Jiang, Ph.D.
    President, Chief Executive Officer and Director

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Wenbin Jiang, William McCombe and Valerie Barnett, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated:

     

    Name

      

    Title

      

    Date

    /s/ Wenbin Jiang, Ph.D.

       President, Chief Executive Officer and Director    February 28, 2025
    Wenbin Jiang, Ph.D.    (Principal Executive Officer)   

    /s/ William McCombe

       Chief Financial Officer    February 28, 2025
    William McCombe    (Principal Financial and Accounting Officer)   

    /s/ Ming Yan, Ph.D.

       Chief Technology Officer and Director    February 28, 2025
    Ming Yan, Ph.D.      

    /s/ Jack Ball

       Director    February 28, 2025
    Jack Ball      

    /s/ Don Hardison

       Director    February 28, 2025
    Don Hardison      

    /s/ Michael Holder

       Director    February 28, 2025
    Michael Holder      

    /s/ Vera Imper, Ph.D.

       Director    February 28, 2025
    Vera Imper, Ph.D.      

    /s/ Deborah Neff

       Director    February 28, 2025
    Deborah Neff      

     

    II-4

    Get the next $CTKB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTKB

    DatePrice TargetRatingAnalyst
    5/9/2025$4.00Buy → Hold
    TD Cowen
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    12/14/2023$9.00Overweight
    Stephens
    7/19/2023Mkt Perform
    Raymond James
    2/15/2022$27.00 → $18.00Equal-Weight
    Morgan Stanley
    1/6/2022$20.00Overweight
    Piper Sandler
    10/15/2021Outperform
    Cowen
    8/17/2021Outperform
    Cowen
    More analyst ratings

    $CTKB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cytek Biosciences Reports First Quarter 2025 Financial Results

      FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa

      5/8/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025

      FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (NASDAQ:CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at CYTO 2025 and American Association of Immunologists' (AAI) IMMUNOLOGY2025. Designed to streamline workflows, accelerate discoveries, and enhance efficiency, FSP technology will be the focus of a variety of demonstrations, educational workshops and tutorials at these prominent industry gatherings. Flow cytometry plays a crucial role in both research and clinical studies, and Cytek is at the forefront of making this powerful technology more accessible and scalable. By empowerin

      4/29/25 5:00:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

      FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

      4/24/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 4:35:51 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 1:42:15 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/22/24 7:07:27 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mccombe William D. converted options into 33,983 shares and covered exercise/tax liability with 13,237 shares (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      5/21/25 5:57:08 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT AND CEO Jiang Wenbin converted options into 48,679 shares and covered exercise/tax liability with 11,855 shares, increasing direct ownership by 0.70% to 5,261,735 units (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      5/21/25 5:55:40 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CHIEF LEGAL OFFICER Barnett Valerie converted options into 16,876 shares and covered exercise/tax liability with 6,575 shares, increasing direct ownership by 14% to 83,673 units (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      5/21/25 5:54:08 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

      SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      5/15/25 2:07:36 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Cytek Biosciences Inc.

      10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)

      5/8/25 5:21:43 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

      5/8/25 4:11:40 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Financials

    Live finance-specific insights

    See more
    • Cytek Biosciences Reports First Quarter 2025 Financial Results

      FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa

      5/8/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

      FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

      4/24/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

      FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023Expanded total Cytek installed base to 3,034 instruments, with 667 total instruments placed during the full year 2024 Net loss in the year ended December 31, 2024 was $6.0 million compared to net loss of $12.1 million in th

      2/27/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Leadership Updates

    Live Leadership Updates

    See more
    • Cytek Announces Resignation of Chief Operating Officer Chris Williams

      FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef

      9/12/24 3:20:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek® Biosciences Names William McCombe Chief Financial Officer

      Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-

      3/19/24 8:00:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services

      FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services. In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and technical application support, building on the recently integrated sales team that combines the original Cytek sales force with the Amnis® and Guava® sales force. "Philippe's extensive global sales and marketing experience as an executive at several life science companies, incl

      8/28/23 5:30:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cytek Biosciences downgraded by TD Cowen with a new price target

      TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

      5/9/25 8:41:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences downgraded by Goldman with a new price target

      Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

      1/31/25 6:59:30 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Stephens initiated coverage on Cytek Biosciences with a new price target

      Stephens initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $9.00

      12/14/23 6:55:41 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials